A budget impact analysis of the introduction of erythropoiesis stimulating agent subsequent entry biologics for the treatment of anemia of chronic kidney disease in Canada

BACKGROUND: In Europe, epoetin subsequent entry biologics (SEBs) have been in use since 2007. Canadian patents of erythropoietin stimulating agents are expiring in 2014, therefore it is predicted that epoetin SEBs will penetrate the Canadian market in the near future. OBJECTIVE: To estimate the econ...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsao, Nicole W, Lo, Clifford, Leung, Marianna, Marin, Judith G, Martinusen, Dan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4349794/
https://www.ncbi.nlm.nih.gov/pubmed/25780617
http://dx.doi.org/10.1186/s40697-014-0028-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4349794/
https://www.ncbi.nlm.nih.gov/pubmed/25780617
http://dx.doi.org/10.1186/s40697-014-0028-3

Ejemplares similares